Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tc99m-MAA for Dosimetry Planning in Lung Cancer
NCT04105283Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Aug 2020
- Primary completion
- Jun 2024
- Modality
- Radiopharmaceutical
- Countries
- 1
01
Overview
Phase 1, open-label trial of technetium Tc 99m macroaggregated albumin in lung cancer, sponsored by Massachusetts General Hospital. Primary endpoint: Calculation of Tc99m-MAA uptake within the tumor and surrounding structures at 2 years. Started Aug 2020; status: completed.
02
Drugs
technetium Tc 99m macroaggregated albumin
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT04105283.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04105283.